OneSource Specialty Pharma on Tuesday announced unaudited consolidated results for the quarter ended September 30, 2026, with net profit surging 448.2% year-on-year to Rs 57.48 crore (yaani about Rs 57.5 crore), up from Rs 10.48 crore in the same quarter last year, CNBC-TV18 and Angel One reported from the company's exchange filing.

Source: CNBC-TV18 via TradingView

Revenue from operations rose 37.4% to Rs 516.2 crore from Rs 376 crore a year ago, while total income climbed 36.5% to Rs 517.20 crore, Angel One reported. Earnings before interest, tax, depreciation and amortisation (EBITDA) jumped 53% to Rs 163.3 crore, with the EBITDA margin expanding to 31.6% from 28.4% a year earlier, CNBC-TV18 reported.

Source: Angel One

Rs 57.48 crQ2 net profit
+448%Profit growth year-on-year
Rs 516.2 crRevenue, up 37.4%
31.6%EBITDA margin

Sequentially, net profit more than doubled from Rs 25 crore in the June quarter, and half-year net profit rose to Rs 82.48 crore from Rs 10.30 crore a year ago, Angel One reported. The company commercialised 12 new products across North America, Latin America and the MENA region during the quarter, driven by new drug-device combination capacity and strong execution of master services agreements.

Source: Angel One

The company commercialised its second cartridge line during the quarter while its third line completed factory acceptance testing, and it recorded six new wins including two biologics programmes, taking its customer base to more than 82 logos, DSIJ reported. Management retained its FY28 outlook of USD 400 million in organic revenue (yaani roughly Rs 3,800 crore) and USD 160 million in EBITDA, the report said.

Source: DSIJ

Shares of OneSource — the demerged entity of Strides Pharma together with the CDMO business of Steriscience Specialties — surged over 8% in Tuesday trade after the results, CNBC-TV18 reported. This is an earnings report, not investment advice.

Source: CNBC-TV18 via TradingView